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ABSTRACT 
In medical follow-up study, the diseases recurrent processes evolved in continuous time and 
the patients are usually monitor at distinct and different intervals. Therefore, most of the 
existing methods that assumed identical observation processes might provide misleading 
results in this case. To address this, a nonparametric test based on integrated weighted 
different between the mean cumulative functions which characterized both the recurrent 
processes and observation processes with condition on treatment is proposed to allow unequal 
observation processes. The empirical power of the proposed test has been investigated via 
Monte Carlo simulation study and bladder tumour case study. The results arein line with 
earlier research; the proposed test procedure works well for practical situations and had a 
good power in detecting treatment difference. 
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1. INTRODUCTION 
In medical follow-up study, patients are usually observed at several irregular time points, the 
actual time of diseases occurrences are unknown and only the number of occurrences between 
subsequence follow-up is recorded. These data are known as panel count data [11]. The 
example of panel count datathat given in this paper arising from bladder tumours study 
conducted by the Veterans Administration Cooperative Urological Research Group [4]. All 
patients had superficial bladder tumours history, the tumours were removed and patients were 
randomized to one of the three treatments, placebo, thiotepa or pyridoxine. These patients 
experienced several recurrences during the follow-up study. The number of new tumours 
discovered at each follow-up was recorded and were removed at clinical visits. Furthermore, 
the number of clinical visit and the observation times are varying across the patients. The 
main interest in this paper is to compare the effectiveness of different treatments in medical 
follow-up studies that account for unequal observation processes.  
In medical, the diseases recurrent processes evolved in continuous time and the patients are 
often monitor at distinct time and different time intervals. In other words, the observation 
processes are not identical distributed. Most of the existing methods assumed that the 
observation processes for the patients in different treatment groups are identical distributed 
[2], [3, 8-9, 16, 20]. There exist limited literatures for nonparametric comparison, which 
consider unequal observation processes between treatments [7, 12, 19].As medical follow-up 
data involves more than one observation time point for each subject that may vary across 
subject and the number of subject in each treatment groups may vary across treatments, the 
existing methods which assume identical observation processes may not be feasible in 
practice. To address this, a multi-sample distribution free test based on the integrated 
weighted different between mean cumulative functions that characterized the recurrences and 
observation processes with condition on treatment group is present in this paper.  
 
2. FORMULATION 
2.1. Basic Notation  
Consider k+1 different treatment groups of independent subjects in a recurrent event study 
with total sample size n. Suppose only panel count data are available and observation 
P. L. Tan et al.             J Fundam Appl Sci. 2017, 9(6S), 147-161              149 
 
processes are different for the subjects from different groups. Let n1 denote the number of 
subjects in the lth group and slthe set of indices for subjects in group l where n1 + n2 + … + 
nk+1 = n. Also let Nil(t) denote the counting process of the total number of recurrent event 
occurrences up to time t from subject i in lth group with Λl (t;Zi) = E[Nil(t)|Zi] the marginal 
expected number of recurrent events up to t of Nil(t) given Zi for i in sl,l = 1, … , k + 1 and Zi 
is a group-indicator associated with subject i.  
For panel count data, each subject is observed only at discrete time points where the ordered 
distinct observation time points for subject i is denote by Ti,1< Ti,2< … < Ti,mj, j = 1, 2, … ,mi 
with mi representing the total number of observation time points for subject i. Let Ci denote 
the censoring or follow-up time of subject i and τ be the longest follow-up time of all subjects 
in the study. The observed data are taken to be independent and identical copies of Diwhere 
the observation data consist of Di = {Ni, Zi, Ci, Tij, mj} and are independent of the counting 
process Ni's.The union of all distinct observation time points denote byt1, t2, … , tmand the 
censoring times for subject iis the last observation time point for subject i in [0, τ]. 
2.2. The Observation Processes 
Fig. 1 displays the distribution of the clinical visits for placebo treatment and thiotepa 
treatment in bladder tumour case study. It appears that the patients in the thiotepa group have 
more follow-up as compared to the patients treated with placebo treatment. The observation 
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Fig.1.Distribution of clinical visits for Placebo treatment and Thiotepa treatment 
To deal with the unequal observation processes between treatment groups, the number of 
observations formulated is proportional between groups as it fit most of the event history 
analysis. An example from bladder tumour study is shown in Fig. 2. 
 
Fig.2. Cumulative number of clinical observations for Placebo treatment and Thiotepa 
treatment 
The total number of observation for subject i is formulated as model in Equation (1).  
  exp iim Z  (1) 
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where γ = 0 means the observation processes between two groups are equal and otherwise γ ≠ 
0. 
2.2. The Recurrence Processes 
In order to mimic the situation tested in this paper, the recurrence event, Nil's are assume 
follow a mixed Poisson processes that result more variability as compared with Poisson 
processes. The mean recurrence at time t for lth treatment group is the proportion of total 
number of recurrence observed in lth treatment group at time t over total number of 
























The mean function of recurrent event occurred up to time t from subject i conditioning on 


















   (3) 
where λ0(t) is known baseline mean, µ(t) common mean of Ni(t) and γ is a parameter 
representing the difference between two groups. 

















  (4) 
The mean cumulative function given treatment group is accumulate of the proportion of the 
product of total number of patient at risk in lth treatment group and mean tumour recurrenceto 
the size of the risk set observed at time tj, Y(tj) as written in Equation (5). 










where   ( )j j i
i
I t CY t  denote the at risk indicator prior to time t.  
2.2. The Test Statistics 
The proposed test statistic has the form of integrated weighted different between 
group-specific mean and the overall mean as given in Equation (6). 
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Followed [6-7], γ can be estimated by solving the partial likelihood score in Equation (7)  
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The null hypothesis can be test based on statistics      '1 ˆ*   ˆˆT     V  the null 
distribution can be approximate by a chi-square distribution with k degree of freedom.     
is given in Equation (10). 
    l
l
     (10) 
In [5] showed that     is asymptotically normal with mean 0 and the variance can be 
consistently estimated by Equation (11). 
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Also,  ia , ib  and  i  are given in Equation (16)-(18). 
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3. SIMULATION STUDY  
The Monte Carlo simulation study is conducted with k = 1 and condition on given treatment 
group covariate Zi where Zi = 0 for i in s1 (group 1) and Zi = 1 for i in s2 (group 2). All of the 
results are based on 5000 replications at a significance level of α = 0.05. The computation for 
the simulation was carried out in written R function using version 3.2.5 of the R statistical 
software.  
The number of observation for subject i, mi is generated based on mi = exp (γZi), γ = 0 means 
the observation processes between treatment groups are equal. For unequal observation 
processes, γ = 0.1, 0.2, 0.3. Given mi, the follow-up times Ti1, T2 , … , Timi  for subject i are 
sampled from Uniform distribution over (0,τ) with τ = 10 and τ = 20 and the censoring time of 
subject i, Ci is the last follow-up time of subject i, Timi. Then, t1, t2, … , tm is the unique order 
statistics of m observations of all follow-up times. The panel count data Ni's are generated 
based on 
   ( ) ( ) ( ) ( ) ( ) ( ), ,1 ,2 ,1 , , 1N T N T N T N T N T N Ti i j i i i i i i i i j i i j        
and 
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 0 , , 1( ) ( ) ~ ( )exp( ), , 1 i i j i j iN T N T Poisson v t t Zi i j i i j     
where λ0 (t) = 1, β = 0.1, 0.2, 0.3.  
For mixed Poisson processes, vi's are generated from Gamma distribution with shape 
parameter 2 and scale parameter of 0.5. For illustration, the data generated with γ = 0.2, β = 
0.2 and τ = 10 is showed in Fig. 3. 
 
Fig.3. Step chart of the simulated data for cumulative mean recurrences 
The test's performance is investigated through its power which is also the percentage of the 
test rejecting the false null hypothesis. The null hypothesis of testing no difference between 
mean cumulative function of treatments is rejected if p-value is less than 0.05. The asymptotic 
approximation of the test in Equation (10) is checked through the plot of the standardized test 
statistic against its theoretical quantile, which is showed in Fig. 4. 
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Fig.4. Quantiles plot of standardized test statistics with n1=n2=50 and γ=β=0.2 
The asymptotic approximation of the test for  1nW , n = 100 given in Fig. 4 is quite good. 
Similar plots are obtained for other tested situations. The asymptotic approximation of the test 
statistics get closer to normal distribution as the sample size increased. 
Tables 1 present the power of the proposed test for τ = 10 and τ = 20 respectively. The power 
of the test procedures increase when the sample sizes increase. Similar results are obtained for 
when the length of follow-up period increased from τ = 10 to τ = 20. Overall, the performance 
of the proposed test gives a good power to detect treatment differences under the tested 
situations. In [12] showed that the test worked well even when the sample sizes were 
imbalanced between two treatment groups.  
Table 1. The empirical power for the proposed test 
   
τ = 10 
  
τ = 20 
 
γ n1 n2 β = 0.1 β = 0.2 β = 0.3 β = 0.1 β = 0.2 β = 0.3 
0 10 10 0.9584 0.9648 0.9662 0.8970 0.8606 0.9130 
 
15 15 0.9818 0.9830 0.9800 0.9862 0.9832 0.9758 
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30 30 0.9866 0.9890 0.9818 0.9950 0.9940 0.9938 
 
50 50 0.9986 0.9994 0.9986 0.9996 0.9996 0.9998 
0.1 10 10 0.9650 0.9710 0.9666 0.9596 0.9324 0.9624 
 
15 15 0.9858 0.9878 0.9848 0.9868 0.9848 0.9798 
 
30 30 0.9920 0.9880 0.9866 0.9980 0.9982 0.9952 
 
50 50 0.9996 0.9984 0.9990 0.9984 0.9992 0.9976 
0.2 10 10 0.9608 0.9712 0.9560 0.9302 0.9306 0.9308 
 
15 15 0.9778 0.9716 0.9576 0.9942 0.9920 0.9864 
 
30 30 0.9932 0.9912 0.9798 0.9958 0.9952 0.9874 
 
50 50 0.9988 0.9988 0.9986 0.9986 0.9996 0.9986 
0.3 10 10 0.9718 0.9604 0.9625 0.9482 0.9154 0.9136 
 
15 15 0.9810 0.9782 0.9716 0.9888 0.9830 0.9812 
 
30 30 0.9942 0.9922 0.9814 0.9944 0.9882 0.9888 
 
50 50 0.9992 0.9996 0.9994 0.9972 0.9978 0.9978 
 
4. BLADDER TUMOUR STUDY 
The nonparametric test described in previous sections will be illustrated by reproduced the 
data from the Veterans Administration Co-operative Urological Research Group (VACURG) 
and the data are presented in [1]. The original data consist of patients with history of 
superficial bladder tumours and treated with placebo, thiotepa and pyridoxine treatments. The 
third treatment pyridoxine was not included in the first part of data analysis as it did not have 
significant effect in reducing the recurrence of bladder tumour as discussed in [4, 10]. 
However, the results of multi-sample comparison are shown in Table 2 for comparison with 
existing nonparametric methods[3,16, 19]. 
The data consist of 85 patients with 47 patients assigned in placebo group and 38 patients in 
thiotepa group. The observed data included the follow-up time and the numbers of recurrent 
tumours during the follow-up study as well as additional information on baseline covariates 
on the size of the largest initial tumour and the number of initial tumours. The initial tumours 
were removed before enter to 53 months of follow-up. The multiple recurrences of tumours 
during the study are recorded.   
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Fig. 5 shows the mean cumulative functions of occurrence of the bladder tumours for both 
treatment groups. It appears to be not much difference in early follow-up, but over time, it’s 
seem to be different and are proportional to each other. The patients treated with placebo 
treatment have higher recurrences compare to those treated with thiotepa treatment. 
Additionally, the thiotepa treatment seems to be effective in reducing the recurrences of 
bladder tumours where the occurrences of bladder tumours are not obvious. Thus, the main 
interest is to test whether the treatment difference is statistically significant. 
 
Fig.5.Mean cumulative number of recurrence tumours 
Let Z = 0 for patients who treated with placebo and Z = 1 for patients who treated with 
thiotepa. The proposed test wascarried out under different weight processes describe in 
Equation (20) - (22). 
    1 1nW t   (20) 
      2 1 ,1 i
n
n i mi
W t n I t t

   (21) 
    3 21n nW W  (22)  




nW , the proposed test yielded T*=3.5028, 
3.3064 and 3.7795 with p-values of 0.0613, 0.069 and 0.0519 respectively. The proposed test 
rejects the null hypothesis at 10% level of significance.These indicated that the mean 
recurrence of the bladder tumours is significantly different across treatment groups.The 
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proposed test has similar conclusion as discussed in [4, 10], where the treatment differences 
are statistical significance. 
Table 2 shows the comparison of the proposed method with existing nonparametric methods 
where in [3] based on nonparametric maximum likelihood estimator (NPMLE) and in [16] 
based on nonparametric maximum pseudolikelihood estimator (NPMPLE), both assumed 
identical observation processes while in [19] based on isotonic regression estimator (IRE) 
which assumed unequal observation processes across treatment groups.  
Table 2.P-values comparison for Multi-sample test on bladder tumour data 
Test  W(1) W(2) W(3) 
Proposed Test Test statistics 6.6215 6.0534 5.3456 
 p-values 0.0365 0.0485 0.0691 
[3] Test statistics 3.617, 3.269 1196123, 300179 489000, 121908 
 p-values 0.164, 0.195 <10-8 <10-8 
[16] Test statistics 4.9281 3.8682 4.9527 
 p-values 0.0851 0.1445 0.0840 
[19] Test statistics 5.2805 0.0379 21.7701 
 p-values 0.0713 0.9812 0.00002 
The test results of [3] based on NPMLE are more significant than others methods with  2nW  
and  3nW , while the unweighted test failed to detect the treatment difference. On the other 
hand, test based on [16, 19] failed to reject the null hypothesis with  2nW .This may be due to 
the test based on the use of isotonic regression estimator of the mean functions crossing at the 
early to middle follow-up time. In [19] showed that the treatments are significantly different 
at late follow-up period at 5% level of significance. In [16] suggested that the treatment 
differences are significant at 10% level of confidence with weight process  1nW  and 
 3
nW . 
It appears that the proposed test is more effective than the existing tests in detecting the 
departure from null hypothesis with all three weight processes. The results also show that in 
[16] which assumed the observation processes are independent and identical across treatment 
groups is less significant as compared with the methods which considered unequal 
observation processes. In the presence of different observation processes, the tests assume the 
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observation processes are identical across treatment groups might provide misleading results. 
However, in [3] with weighted test gives significance results due to the estimator used are 
more efficient than other estimator as showed by [13]. Thus, one should choose the right test 
with proper weight process as most of the existing nonparametric comparison procedures are 
applicable to pre-schedule observations, where the observation processes across treatments 
are identical. 
 
5. CONCLUSION  
This paper discussed the distribution free test to compare treatment efficiency in medical 
follow-up study when the observation processes are differed across treatments. Based on the 
simulation study and the bladder tumour case study, the proposed test works well for 
situations consider here. Most of the existing nonparametric test for panel count data assumed 
identical observation processes between treatments [2-3, 8-9, 16, 20]. In reality, this 
assumption might not be true as shown in bladder tumour case study and might provide 
misleading results. Thus, one should carefully choose a test procedure based on the tested 
situations. 
There exist limited study on nonparametric test and a lot of further works still need to be done. 
The proposed test is concerned on univariate nonparametric comparisons with time 
independent covariate. One might consider the case for time dependent covariates. Also, the 
proposed test is depending on the assumption of independent censoring. In order words, the 
censoring processes are independent of the observation processes and the recurrent processes. 
Furthermore, researcher might be interest in studying the treatment differences for bivariate or 
multivariate cases for future study or consider informative censoring cases as in [17-18]. 
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